T. Rowe Price Associates
VIR icon

T. Rowe Price Associates’s Vir Biotechnology VIR Stock Holding History

T. Rowe Price Associates’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$862K Buy
96,145
+14,534
+18% +$116K ﹤0.01% 2228
2025
Q4 		$493K Buy
81,611
+34,475
+73% +$205K ﹤0.01% 2404
2025
Q3 		$270K Buy
47,136
+4,201
+10% +$21.5K ﹤0.01% 2655
2025
Q2 		$217K Sell
42,935
-31,743
-43% -$170K ﹤0.01% 2677
2025
Q1 		$484K Buy
74,678
+3,346
+5% +$29.8K ﹤0.01% 2259
2024
Q4 		$524K Buy
71,332
+3,506
+5% +$27.7K ﹤0.01% 2261
2024
Q3 		$509K Buy
67,826
+9,983
+17% +$86.7K ﹤0.01% 2235
2024
Q2 		$515K Buy
57,843
+4,464
+8% +$42.8K ﹤0.01% 2178
2024
Q1 		$541K Sell
53,379
-33,225
-38% -$338K ﹤0.01% 2178
2023
Q4 		$872K Sell
86,604
-149,323
-63% -$1.36M ﹤0.01% 1933
2023
Q3 		$2.21M Sell
235,927
-566,107
-71% -$8.07M ﹤0.01% 1420
2023
Q2 		$19.7M Buy
802,034
+415,089
+107% +$10.4M ﹤0.01% 941
2023
Q1 		$9.01M Buy
386,945
+1,297
+0.3% +$33.2K ﹤0.01% 1076
2022
Q4 		$9.76M Buy
385,648
+39
+0% +$956 ﹤0.01% 1057
2022
Q3 		$7.44M Buy
385,609
+209,070
+118% +$5.31M ﹤0.01% 1121
2022
Q2 		$4.5M Sell
176,539
-273,824
-61% -$6.39M ﹤0.01% 1435
2022
Q1 		$11.6M Sell
450,363
-147,070
-25% -$4.36M ﹤0.01% 1347
2021
Q4 		$25M Buy
597,433
+560,914
+1,536% +$22M ﹤0.01% 1229
2021
Q3 		$1.59M Sell
36,519
-39,334
-52% -$1.7M ﹤0.01% 1834
2021
Q2 		$3.59M Buy
75,853
+13,874
+22% +$631K ﹤0.01% 1578
2021
Q1 		$3.18M Sell
61,979
-3,437
-5% -$185K ﹤0.01% 1566
2020
Q4 		$1.75M Buy
65,416
+38,960
+147% +$1.27M ﹤0.01% 1689
2020
Q3 		$908K Buy
+26,456
New +$1.14M ﹤0.01% 1839

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

T. Rowe Price Associates's VIR Position: Q1 2026 in Review

T. Rowe Price Associates increased its Vir Biotechnology (VIR) stake by 18% in Q1 2026, buying an estimated $116K and bringing the position to 96,145 shares worth $862K. The position accounts for ﹤0.01% of the portfolio, ranked #2228.

T. Rowe Price Associates first reported a position in VIR in Q3 2020 and has held it in 23 quarters since. The position peaked at $25M in Q4 2021. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • T. Rowe Price Associates held 96,145 shares of Vir Biotechnology worth $862K as of Q1 2026.
  • T. Rowe Price Associates bought 14,534 Vir Biotechnology shares in Q1 2026, an estimated $116K.
  • Vir Biotechnology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2228 holding.
  • T. Rowe Price Associates first reported a position in Vir Biotechnology in Q3 2020 and has held it in 23 quarters since.
  • T. Rowe Price Associates's Vir Biotechnology position peaked at $25M in Q4 2021.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.